Cancer Stem Cell News Volume 9.32 | Aug 26 2020


    2020-08-26 | CSCN 9.32

    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 9.32 – 26 August, 2020

    Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells

    Detailed metabolomic analysis revealed elevated nicotinamide metabolism in relapsed leukemia stem cells (LSCs), which activated both amino acid metabolism and fatty acid oxidation to drive OXPHOS, thereby providing a means for LSCs to circumvent the cytotoxic effects of venetoclax and azacitidine therapy.
    [Cell Stem Cell]

    AbstractGraphical Abstract

    Scientific resources to support your hematopoiesis research. Learn More!
    PUBLICATIONSRanked by the impact factor of the journal

    β-Catenin and γ-Catenin Are Dispensable for T Lymphocytes and AML Leukemic Stem Cells

    In an MLL-AF9 AML mouse model, genetic deletion of β-catenin, or even all four Tcf/Lef family transcription factors that interact with β-catenin, did not affect AML onset in primary recipients, or the ability of leukemic stem cells in propagating AML in secondary recipients.


    E2F7−EZH2 Axis Regulates PTEN/AKT/mTOR Signaling and Glioblastoma Progression

    Functional studies showed that E2F7 promoted cell proliferation, cell-cycle progression, cell metastasis and tumorigenicity abilities in vitro and in vivo.
    [British Journal of Cancer]


    Different Role of YKL-40 in Glioblastoma Is a Function of MGMT Promoter Methylation Status

    The authors performed in vitro and in vivo experiments and six human IDH1/2 wild-type glioblastoma stem-like cells were established and studied to determine a potential interaction of YKL-40 and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation.
    [Cell Death & Disease]

    Full Article

    D3 Signaling-Induced Decreases in IRX4 Inhibits NANOG-Mediated Cancer Stem-Like Properties and Gefitinib Resistance in NSCLC Cells

    Researchers discovered that increased iroquois-class homeodomain protein 4 (IRX4) was related to gefitinib resistance in non-small cell lung cancer (NSCLC) cells. Knockdown of IRX4 inhibited cell proliferation, sphere formation, and the expression of CD133, ALDH1A1, NANOG, Sox2 and Notch1, and the transcriptional activity of NANOG promoter.
    [Cell Death & Disease]

    Full Article

    Exon-v6 from CD44v6-Containing Isoforms Influences Chemotherapy Response and Self-Renewal Capacity of Gastric Cancer Cells

    Investigators demonstrated that exon-v6 specific removal from CD44v isoforms increases cell sensitivity to cisplatin and impairs gastric cancer cells self-renewal.

    Full Article

    Infection Promotes the Formation of Glioma Stem Cells from Glioblastoma Cells through the TLR9/NEAT1/STAT3 Pathway

    Infection of patient-derived glioma cells with adenovirus (ADV) increased the formation of tumor spheres. ADV infection upregulated stem cell markers and in turn promoted the capacities of self-renewal and multi-lineage differentiation of the infected tumor spheres.
    [Cell Communication and Signaling]

    Full Article

    of Circulating Breast Cancer Cell Heterogeneity and Interactions with Peripheral Blood Mononuclear Cells

    Scientists captured circulating tumor cells (CTCs) from the peripheral blood of breast cancer patients using size‐exclusion membranes followed by scRNA‐seq of enriched CTCs and carry‐over peripheral blood mononuclear cells.
    [Molecular Carcinogenesis]


    In Vitro and In Vivo
    Characterization of Cancer Stem‐Cell Subpopulations in Oral Squamous Cell Carcinoma

    In vitro behavior of FACS‐sorted CD44HighESAHigh CSCs and CD44HighESALow CSCs from oral squamous cell carcinoma cells was characterized by their ability to form colonies, migrate, proliferate, and to invade a solid matrix.
    [Journal of Oral Pathology & Medicine]


    Stem Cell Phenotype Is Associated with Mutational Profile in Acute Myeloid Leukemia

    The authors investigated the associations between genetic information and the various leukemic stem cell (LSC) phenotypes, namely multipotent progenitor-like, lymphoid primed multipotent progenitor-like and granulocyte-macrophage progenitors-like LSC in 52 acute myeloid leukemia patients.
    [Korean Journal of Internal Medicine]


    of Photobiomodulation on Cellular Viability and Cancer Stem Cell Phenotype in Oral Squamous Cell Carcinoma

    Researchers evaluated in vitro, the effects of photobiomodulation (PBM), with the same dosimetric parameters as those used in the clinic for oral mucositis prevention and treatment, on oral squamous cell carcinoma cellular viability, as well as PBM’s effect on cancer stem cell properties and its phenotype.
    [Lasers in Medical Science]

    Full Article

    Tumors Are 3D. Shouldn't Your In Vitro Model Be? Learn More.

    of Oral Mucosal Stem Cell Markers in Oral Submucous Fibrosis and Their Reactivation in Malignant Transformation

    Investigators review the expression of oral mucosal stem cell markers in oral submucous fibrosis (OSF), oral potentially malignant disorders and oral squamous cell carcinoma to understand the role of basal cells in potentiating cancer stem cell behaviour in OSF.
    [International Journal of Oral Science]

    Full Article

    Rewiring in the Promotion of Cancer Metastasis: Mechanisms and Therapeutic Implications

    The authors summarize the recent discoveries involving metabolism and tumor metastasis, and emphasize the promising molecular targets, with an update on the development of small molecule or biologic inhibitors against these aberrant situations in cancer.

    Full Article


    Novartis Investigational Novel STAMP Inhibitor Asciminib (ABL001) Meets Primary Endpoint of Phase III Chronic Myeloid Leukemia Study

    Novartis announced that, at primary analysis, the Phase III ASCEMBL study met its primary endpoint of statistically significant superiority in major molecular response rate at 24 weeks for asciminib vs. bosutinib.
    [Novartis AG]

    Press Release

    Expression Therapeutics Announces Success in Developing a Stem Cell Lentiviral Gene Therapy for Hemophagocytic Lymphohistiocytosis (HLH)

    Primary HLH is a family of devastating primary immune deficiencies with limited treatment options and no gene therapies under clinical testing. Expression Therapeutics has developed a promising and potentially curative gene therapy candidate for familial HLH type 3.
    [Expression Therapeutics (PR Newswire Association LLC.)]

    Press Release


    Cancer Research & Oncology 2020

    October 7 – 8

    > See All Events


    Postdoctoral Associate – RNA Epigenetics in Cancer Stem Cells

    Sanford Burnham Prebys Medical Discovery Institute – La Jolla, California, United States

    Faculty Position – Prostate Cancer Biology and Cancer Epigenetics

    Northwestern University – Chicago, Illinois, United States

    Postdoctoral Fellowship – Hematopoiesis, Leukemia, and Bone Marrow Failure Syndromes

    The University of Texas Southwestern Medical Center – Dallas, Texas, United States

    Postdoctoral Research Fellow – Hematopoiesis, Marrow Failure and Myeloid Leukemia

    Cincinnati Children’s Hospital Medical Center – Cincinnati, Ohio, United States

    Positions – Cancer Epigenomics

    West Virginia University – Morgantown, West Virginia, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Science News Cancer Stem Cell News
    Archives Contact Us
    Cancer Stem Cell News Twitter